These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
287 related items for PubMed ID: 23054947
1. A new era in the treatment of chronic hepatitis C infection. Jothimani D, Chandy GM, Conjeevaram H. Indian J Gastroenterol; 2013 Mar; 32(2):71-9. PubMed ID: 23054947 [Abstract] [Full Text] [Related]
2. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase? Pascale A, Serfaty L. J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419 [Abstract] [Full Text] [Related]
3. Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials. Sitole M, Silva M, Spooner L, Comee MK, Malloy M. Clin Ther; 2013 Feb; 35(2):190-7. PubMed ID: 23369368 [Abstract] [Full Text] [Related]
4. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection. Ferenci P, Reddy KR. Antivir Ther; 2011 Feb; 16(8):1187-201. PubMed ID: 22155901 [Abstract] [Full Text] [Related]
5. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1. Manns MP, Markova AA, Calle Serrano B, Cornberg M. Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568 [Abstract] [Full Text] [Related]
11. Triple therapy with boceprevir or telaprevir for prior HCV non-responders. Asselah T. Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):455-62. PubMed ID: 23199504 [Abstract] [Full Text] [Related]
12. Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders. Forestier N, Zeuzem S. Liver Int; 2012 Feb; 32 Suppl 1():44-50. PubMed ID: 22212571 [Abstract] [Full Text] [Related]
13. New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Asselah T, Marcellin P. Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141 [Abstract] [Full Text] [Related]
14. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C. Foote BS, Spooner LM, Belliveau PP. Ann Pharmacother; 2011 Sep; 45(9):1085-93. PubMed ID: 21828346 [Abstract] [Full Text] [Related]
17. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Hézode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, De Ledinghen V, Poynard T, Samuel D, Bourliere M, Alric L, Raabe JJ, Zarski JP, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Chazouilleres O, Abergel A, Guyader D, Metivier S, Tran A, Di Martino V, Causse X, Dao T, Lucidarme D, Portal I, Cacoub P, Gournay J, Grando-Lemaire V, Hillon P, Attali P, Fontanges T, Rosa I, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP, CUPIC Study Group. Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719 [Abstract] [Full Text] [Related]
18. [New agents for the treatment of hepatitis C]. Buti M, Homs M. Enferm Infecc Microbiol Clin; 2012 Mar; 30(3):147-50. PubMed ID: 22118805 [Abstract] [Full Text] [Related]
19. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C. Susser S, Herrmann E, Lange C, Hamdi N, Müller T, Berg T, Perner D, Zeuzem S, Sarrazin C. PLoS One; 2014 Mar; 9(11):e112592. PubMed ID: 25393304 [Abstract] [Full Text] [Related]